Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248). BRIUMVI is a novel monoclonal antibody that targets a unique epitope on ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI ® (ublituximab-xiiy) in patients with ...

The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation ...

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for ...

TG Therapeutics, Inc. NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 healthcare workers in Catalonia who were followed during three years.

A timeline has been set for H-E-B’s upcoming San Marcos location. Construction is slated to begin Sept. 1 and is forecast to be complete in early October 2026, according to a new filing with the ...

Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248). BRIUMVI is a novel monoclonal antibody that targets a unique epitope on ...